After the deal on Allergan, Actavis is preparing to lay off. And focus on China
Fedaisf editorial staff
However, he did not go into the details of the possible restructuring. According to Saunders, there is overlap between the two companies in areas such as human resources and finance. FTA Online News 25/11/2014 Borse Internazionali – ECONOMIA LA STAMPA
Actavis is preparing to reduce its workforce and expand business in China, according to as declared by the chief executive Brent Saunders to Bloomberg Television. Il produttore di farmaci generici, che ha raggiunto l’accordo per rilevare Allergan, produttore del Botox, in un deal da 66 miliardi di dollari, non è però entrato nei dettagli della possibile ristrutturazione. Secondo Saunders esistono sovrapposizioni tra le due società in comparti come risorse umane e finanza.
